Tapio Paljärvi (Tapio Paljarvi)

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 8

Top Topics

Bipolar Disorder

Top Venues

The British journal of psychiatry : the journal of mental science

Acta psychiatrica Scandinavica

The British journal of dermatology

BMJ mental health

This page only lists publications with an associated author ORCID identifier.

Publications

Tapio Paljärvi, Kimmo Herttua, Heidi Taipale, Markku Lähteenvuo, Antti Tanskanen, Jari Tiihonen
Cardiovascular mortality in bipolar disorder: Population-based cohort study. Acta psychiatrica Scandinavica (2024)
Tapio Paljärvi, Kimmo Herttua, Heidi Taipale, Markku Lähteenvuo, Antti Tanskanen, Jari Tiihonen
Cardiovascular mortality in bipolar disorder: Population-based cohort study. Acta psychiatrica Scandinavica 150 (2) (2024)
Markku Lähteenvuo, Tapio Paljärvi, Antti Tanskanen, Heidi Taipale, Jari Tiihonen
Real-world effectiveness of pharmacological treatments for bipolar disorder: register-based national cohort study. The British journal of psychiatry : the journal of mental science (2023)
Tapio Paljärvi, Kimmo Herttua, Heidi Taipale, Markku Lähteenvuo, Antti Tanskanen, Seena Fazel, Jari Tiihonen
Cause-specific excess mortality after first diagnosis of bipolar disorder: population-based cohort study. BMJ mental health 26 (1) (2023)
Tapio Paljärvi, Jari Tiihonen, Markku Lähteenvuo, Antti Tanskanen, Seena Fazel, Heidi Taipale
Mortality in psychotic depression: 18-year follow-up study. The British journal of psychiatry : the journal of mental science (2022)
Tapio Paljärvi, Tess McPherson, Sierra Luciano, Kimmo Herttua, Seena Fazel
Isotretinoin and adverse neuropsychiatric outcomes: retrospective cohort study using routine data. The British journal of dermatology 187 (1) (2022)
Seena Fazel, Tapio Paljärvi
Response to 'Isotretinoin and adverse neuropsychiatric outcomes: retrospective cohort study using routine data': reply from authors. The British journal of dermatology 187 (3) (2022)
Tapio Paljärvi, Sir John Strang, Patrick D Quinn, Sierra Luciano, Seena Fazel
Abuse-deterrent extended-release oxycodone and risk of opioid-related harm. Addiction (Abingdon, England) 116 (9) (2021)